Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.
about
Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancerRoles of resolvins in the resolution of acute inflammationDHA- and EPA-derived resolvins, protectins, and maresins in airway inflammationSpecialized pro-resolving mediators: endogenous regulators of infection and inflammationInhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in miceProfiling the Oxylipin and Endocannabinoid Metabolome by UPLC-ESI-MS/MS in Human Plasma to Monitor Postprandial InflammationBioinformatics: the next frontier of metabolomicsMicrobial, host and xenobiotic diversity in the cystic fibrosis sputum metabolomePlasma metabolomics in human pulmonary tuberculosis disease: a pilot studySerum metabolomics indicate altered cellular energy metabolism in children with cystic fibrosis.Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation.Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosisMetabolomics analysis identifies novel plasma biomarkers of cystic fibrosis pulmonary exacerbation.Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis.Omics approaches in cystic fibrosis research: a focus on oxylipin profiling in airway secretions.Resolvin D1 and Resolvin E1 Promote the Resolution of Allergic Airway Inflammation via Shared and Distinct Molecular Counter-Regulatory Pathways.CFTR activity and mitochondrial function.Exhaled breath condensate eicosanoid levels associate with asthma and its severity.Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediatorsHeart-lung interaction via infectionLipidomics of oxidized polyunsaturated fatty acidsClinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic TargetApplication of metabolomics approaches to the study of respiratory diseases.Sum of the parts: mass spectrometry-based metabolomicsLipidomics applications in health, disease and nutrition research.Oxidized fatty acids as inter-kingdom signaling molecules.Redox balance in cystic fibrosis.The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis.Recent applications of CE- and HPLC-MS in the analysis of human fluids.Biomarkers for cystic fibrosis drug development.Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.Proresolving Action of Docosahexaenoic Acid Monoglyceride in Lung Inflammatory Models Related to Cystic Fibrosis.Regulation of inflammation by lipid mediators in oral diseases.Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators.Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation.Lessons learned from metabolomics in cystic fibrosis.3,3',4,4',5-Pentachlorobiphenyl (PCB 126) Decreases Hepatic and Systemic Ratios of Epoxide to Diol Metabolites of Unsaturated Fatty Acids in Male Rats.
P2860
Q26741524-E2E565A1-86B8-4A41-B2D3-02029F13F303Q28244502-A481C772-D33E-46C3-9C73-1E7071FB69A0Q28269550-C2DD0F27-CCA4-4961-AAC5-443ABE156AAFQ28271331-A4413168-2EEE-4E50-BC08-AD70D92169A3Q28395856-6332C839-61D2-4739-BA96-EFD2604E3096Q28546635-6FEEB434-518F-4310-850C-C3BCDB664BA7Q28652509-489DD7EC-C519-48A7-9458-5B0B87668C34Q28829667-320E5F90-713D-4081-A226-095B7FD0F21BQ34343488-25C62F90-8EFA-449F-B218-88288088B6FDQ34813994-E877F81C-5BAF-439E-B5D9-922037ACC448Q35072759-06DABFC1-952A-4CCC-B522-A5FCB411B7BAQ35569460-0B4F9344-9AD8-497D-B7FF-B9FA09D3C1C3Q35675928-4CDE7E38-8B1C-42F9-B14A-87D8FAB280D4Q35914614-CA46D7AD-6244-4144-B84E-05CBEB6528DDQ36112019-C72F8264-897F-45B8-A420-4E50D9238700Q36492325-C2FAAA94-6263-45EC-B5F6-272BF16E6DB4Q37133567-46AA169F-424F-4260-B97B-325B51F1D935Q37138368-53CCF4D1-E8EA-401B-831B-9836DE3C4DB0Q37577177-C689DB4F-A7E8-446F-8D89-10B45F1A3B67Q37679759-68A085D7-4865-48E3-A0ED-ACBBB8278B5CQ37710484-98449660-B7FC-461C-9A54-441AED1EA3AFQ37731230-B3DAB485-FD1B-4DBE-9367-1F25AA099A5DQ38050515-FF3BA678-2029-4976-AA72-F27BFD49934BQ38084744-B8940D96-5A13-4336-929E-7A88C7A4EAF0Q38111301-9BBD9282-7C19-442D-B0D3-4207B12DC37EQ38180557-ABAA9D8B-6CD0-441D-A5E3-CECDCF22BEF6Q38198442-4B0BBDB9-26DC-4C0D-9479-BA61BB72CF58Q38268820-2BDBEE02-0E22-4604-B7D2-2E8FD14FEF47Q38596722-CEB3BED5-AB56-4C52-88D4-2427D98DC3CBQ38755600-86944D7B-FF0B-414D-9C6D-513AA0A6E74EQ38796210-13C92D43-630B-4AC9-B634-12BB4E961E01Q38898556-52F5AE0E-BB7B-4380-A56E-5B2CDBA54025Q38899898-9384D3AC-CF3D-4EDC-905A-0564FA6C7873Q39046533-146A46AD-E594-495E-B83C-C54B3D8829F6Q39088075-0A2F34C4-91FA-4853-B609-2A1D3180D86BQ39163938-1D322D30-244B-4632-9C8D-45C4035EF014Q39197238-DDF9B4B5-4DFF-4398-ACA8-EE851FEA4D78Q39271007-9AEEB831-4CDE-4F5A-98EA-595C52826B2DQ40920707-0AEDC45A-1996-41A7-8E04-51F21C3791A1Q42404212-4B695152-71FA-42B0-A3EA-404CB215015F
P2860
Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Metabolomic profiling of regul ...... dult cystic fibrosis patients.
@ast
Metabolomic profiling of regul ...... dult cystic fibrosis patients.
@en
type
label
Metabolomic profiling of regul ...... dult cystic fibrosis patients.
@ast
Metabolomic profiling of regul ...... dult cystic fibrosis patients.
@en
prefLabel
Metabolomic profiling of regul ...... dult cystic fibrosis patients.
@ast
Metabolomic profiling of regul ...... dult cystic fibrosis patients.
@en
P2093
P2860
P1476
Metabolomic profiling of regul ...... adult cystic fibrosis patients
@en
P2093
Brian M Morrissey
Bruce D Hammock
Carroll E Cross
Jason P Eiserich
P2860
P304
P356
10.1016/J.FREERADBIOMED.2012.05.001
P50
P577
2012-05-08T00:00:00Z